Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Prospective, Observational Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)

NCT03059953 is registered in ClinicalTrials.gov with Genesis Pharma S.A. as lead sponsor.

NCT NCT03059953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Prospective, Observational Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)
Lead sponsor
Genesis Pharma S.A.
Phase
Observational
Overall status
Completed
Start date
April 7, 2017
Completion date
April 24, 2019
Enrollment
302 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate plaque psoriasis